18 results about "Kininogen" patented technology

The present invention provides compositions and methods for inhibiting thrombosis in subjects at risk of thrombosis, such as those with a genetic, acquired, or environmental risk of thrombosis. [Solution] The present invention provides RNAi agents, such as double-stranded RNAi agents, that target kallikrein B, plasma (Fletcher factor) 1 (KLKB1) gene, factor XII (Hageman factor (F12) gene, or kininogen 1 (KNG1) gene, as well as methods for inhibiting the expression of the KLKB1 gene, F12 gene, and / or KNG1 gene using such RNAi agents, and methods for treating subjects with hereditary angioedema (HAE) and / or contact activation pathway-related disorders.

The invention provides a preparation method of an aprotinin affinity chromatographic column. Specifically, the aprotinin is used as a raw material and is coupled with CNBr activated agarose gel Focurose 4FF to prepare the aprotinin affinity chromatographic column. The coupling reaction in the preparation method is simple and easy to control, the reaction condition is mild, the operation is convenient, the repeatability is high, and industrial amplification is easy. The affinity column prepared by the invention can completely remove human urinary kallidinogenase in urokinase, and can be repeatedly used for multiple times.

The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and / or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and / or a contact activation pathway-associated disorder.

The invention relates to a method for determining kininogenase and a used kit. On one hand, the invention relates to a kit for determining the content of kininogenase in human plasma, the kit comprises a test solution for testing, an antigen standard substance, a capture antibody, an enzyme-labeled antibody and a test method description file which are separately packaged by containers, and the test solution comprises PBS, PBST, a washing solution, a confining solution, a sample diluent, a stop solution, a coating buffer solution, a color developing solution A and a color developing solution B. The invention also relates to a method for determining the content of kininogenase in human plasma by using the kit. According to the kit and the method provided by the invention, the amount of endogenous kininogenase or exogenous kininogenase in a human body can be accurately and effectively measured, and a beneficial tool is provided for diagnosis and treatment of clinical diseases.

The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and / or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and / or a contact activation pathway-associated disorder.

The application provides a kind of nanobody specifically binding to pancreatic kallikrein, wherein the nucleotide sequence of the nanobody is as shown in any one of SEQ ID No.1, 3, 5.The application also provides corresponding applications.The application successfully screens and identifies anti-pancreatic kallikrein nanobody with good expression activity, uses pichia pastoris system to express and produce, can greatly reduce production cost, and is more conducive to the industrialization of the antibody;It also successfully constructs the purification filler using anti-pancreatic kallikrein nanobody as accessory, and lays a good foundation for subsequent purification of pancreatic kallikrein.

The invention belongs to the technical field of biological medicines, and particularly relates to a heart failure wet syndrome specific biomarker, which is at least one selected from the group consisting of metalloproteinase tissue inhibition factor-3 (Metalloproteinase inhibitor 3, TIMP3), apolipoprotein C-II (Apolipoprotein C-II, APOC2), and kininogen-1 (Kininogen-1, KNG1). Peripheral serum is used as a sample, a 4D-DIA proteomics technology is adopted for screening differential proteins, a targeted proteomics technology is adopted for verification, and three heart failure dampness syndrome specific markers (TIMP3, APOC2 and KNG1) are screened out, have high sensitivity and specificity, can be used for accurate identification of heart failure dampness syndrome patients, and can be used for clinical application. The blank of specific biological markers of the heart failure dampness syndrome at present is filled, the newly found biological marker can provide reliable basis and practical guidance for clinical diagnosis and drug treatment of the heart failure dampness syndrome in the future, and realization of individuation and precision targets of diagnosis and treatment of chronic heart failure is promoted.

The invention provides a pharmaceutical composition for improving diabetic peripheral neuropathy. The pharmaceutical composition is prepared by the following steps: preparing two groups of pharmaceutical compositions and selecting mice suffering from diabetes mellitus of the same type; the preparation method of the pharmaceutical composition comprises the following steps: adding 100mL of sodium chloride solution into 1mg of mecobalamin injection, carrying out intravenous drip, and carrying out intramuscular injection by adopting 40U of pancreatic kininogenase injection; the preparation method of the pharmaceutical composition comprises the following steps: adding 0.45 g of alpha-lipoic acid into 100 mL of a sodium chloride solution, and carrying out intravenous drip; the method comprises the following steps: selecting 53 mice with diabetes mellitus of the same type, and dividing the 53 mice into a research group and a control group; the clinical treatment effect, the adverse reaction occurrence rate and the sensory motor nerve conduction speed after treatment of the pharmaceutical composition used in a research group are obviously superior to those of a control group; the pharmaceutical composition used by the research group can block the neuropathy of diabetes mellitus through various ways and weaken the oxidation reaction of the disease, so that the nerve impulse conduction is accelerated, neuropeptides, nerve factors and the like are promoted to return to normal, and a good treatment effect is achieved.

The application provides a kind of nanobody specifically binding to pancreatic kallikrein, wherein the nucleotide sequence of the nanobody is as shown in any one of SEQ ID No.1, 3, 5.The application also provides corresponding applications.The application successfully screens and identifies anti-pancreatic kallikrein nanobody with good expression activity, uses pichia pastoris system to express and produce, can greatly reduce production cost, and is more conducive to the industrialization of the antibody;It also successfully constructs the purification filler using anti-pancreatic kallikrein nanobody as accessory, and lays a good foundation for subsequent purification of pancreatic kallikrein.

Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of plasma prekallikrein (PKK). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK protein in a cell or animal.

The application provides a kind of nanobody specifically binding to pancreatic kallikrein, wherein the nucleotide sequence of the nanobody is as shown in any one of SEQ ID No.1, 3, 5.The application also provides corresponding applications.The application successfully screens and identifies anti-pancreatic kallikrein nanobody with good expression activity, uses pichia pastoris system to express and produce, can greatly reduce production cost, and is more conducive to the industrialization of the antibody;It also successfully constructs the purification filler using anti-pancreatic kallikrein nanobody as accessory, and lays a good foundation for subsequent purification of pancreatic kallikrein.

An siRNA which inhibits kininogen (KNG) gene expression, a pharmaceutical composition containing the siRNA, and an siRNA conjugate. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide. The siRNA contains a sense strand and an antisense strand. The sense strand contains nucleotide sequence I, nucleotide sequence I having the same length as the nucleotide sequence shown in SEQ ID NO: 1, with no more than three nucleotide differences. The antisense strand contains nucleotide sequence II, nucleotide sequence II having the same length as the nucleotide sequence shown in SEQ ID NO: 2, with no more than three nucleotide differences. The siRNA, the pharmaceutical composition thereof and the siRNA conjugate can effectively treat and / or prevent septicemia.

This invention discloses a detection kit for residual urokinase protein, its preparation method, and its application. The detection kit includes a capture antibody and a detection antibody. The capture antibody includes a polyclonal antibody against residual urokinase protein, and the detection antibody includes a biotin-labeled polyclonal antibody against residual urokinase protein. The polyclonal antibody against residual urokinase protein is obtained by repeatedly immunizing animals with residual urokinase protein as an immunogen. The residual urokinase protein is obtained by further purifying crude human urinary kininogenase by adsorption and removal of urokinase using an affinity column with an anti-urokinase monoclonal antibody. This invention fills the gap in the detection of residual drug proteins in urinary sources. It has high specificity, an antibody coverage rate of over 70%, and a method quantification limit of approximately 4 ng / ml. It has a low detection limit and high sensitivity for residual urokinase protein, requires no expensive instruments, and is easy to operate.

This invention provides reagents and methods for diagnosing renal disease. Differential levels of inosine metabolite, and proteins: apolipoprotein C-I, apolipoprotein C-II, fibrinogen alpha chain, or fibrinogen A-alpha chain, kininogen, Inter-Alpha Inhibitor H4 (ITIH4), keratin Type I cytoskeletol 10 cystatin A, cystatin B and other polypeptides and fragments thereof provide biomarkers of renal disease and are described herein.

The invention discloses a recombinant human pancreatic kininogenase mutant subjected to engineering modification, a composition containing the kininogenase, and application of the mutant enzyme in treatment of related diseases caused by cerebral apoplexy, stroke and hyperglycemia. The modified mutant protein has high activity, high stability and more uniform glycosylation modification characteristics than wild protein, and when the mutant protein is used for treatment, biological potential safety hazards caused by a traditional biological extraction production process can be avoided, the consistency of products is improved, and more stable and effective drug protein is obtained.

The present invention provides a biomarker, a kit and its application for diagnosing abnormal thyroid function. The present invention obtains complement C4-A, C3 / C5 convertase, glutathione peroxidase 3, L-arginine, L-proline and L-glutamate for diagnosing hyperthyroidism through differential screening, integrated feature selection algorithm (EFS), ROC analysis and other bioinformatics analysis methods, and apolipoprotein L1, α-trypsin inhibitor heavy chain H4, kininogen-1, cortisone, cortisol, L-threonine for diagnosing hypothyroidism. Based on the biomarkers of the present invention, corresponding kits and diagnostic equipment can be constructed for accurately diagnosing abnormal thyroid function.

The invention discloses expression of recombinant human urinary kallidinogenase in CHO (Chinese Hamster Ovary) cells. The signal peptide in the human urinary kallidinogenase with the signal peptide disclosed by the invention is the signal peptide of an Sic / SPI type. The method disclosed by the invention can be used for efficiently expressing the human urinary kallidinogenase.